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Formation of c-H2AX in response to DNA double stranded breaks (DSBs) provides the basis for a sensitive
assay of DNA damage in human biopsies. The review focuses on the application of c-H2AX-based meth-
ods to translational studies to monitor the clinical response to DNA targeted therapies such as some
forms of chemotherapy, external beam radiotherapy, radionuclide therapy or combinations thereof.
The escalating attention on radiation biodosimetry has also highlighted the potential of the assay includ-
ing renewed efforts to assess the radiosensitivity of prospective radiotherapy patients. Finally the c-
H2AX response has been suggested as a basis for an in vivo imaging modality.
 2011 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction lational cancer research [4]. H2AX, a variant of the core histoneThe development of biomarkers to monitor and predict the efﬁ-
cacy of cancer chemo- and radiotherapy is a continuing endeavor
in cancer therapy. Whilst macroscopic imaging can be useful, espe-
cially PET using 18F-ﬂuorodeoxyglucose [1], the response time
deems these to be largely retrospective investigations of the re-
sponse to therapy. The same can be said of metabolic markers, such
as the classic example of prostate-speciﬁc antigen (PSA) [2]. Thus
there is a rapidly progressing effort to develop short term response
markers based on tissue-speciﬁc gene and protein expression pro-
ﬁles [3]. For radiotherapy and DNA-targeted chemotherapeutics, a
more direct strategy is to monitor DNA damage and/or the bio-
chemical response to this damage. However, until recently, the
available methods were limited by poor sensitivity (relative to
the size of available biopsy samples) and/or long turn-around time.
Thus the emergence of a rapid, sensitive method to quantify the
DNA damage that is apparent in cells shortly after treatment has
great potential to monitor not only the response of the tumor,
but also the effects of the treatment on ‘‘at risk’’ normal tissues,
to thus assess therapeutic ratio. Assessment of DNA damage in nor-
mal tissues could have predictive value for both acute and long-
term consequences of therapy.
In recent years, a new biomarker, the phosphorylated histone
H2AX, has become a powerful tool to monitor DNA DSBs in trans-f Radiation Oncology, Peter
East Melbourne, VIC 3002,
artin).
er CC BY-NC-ND license.H2A family, contains a unique SQ motif within its C-terminal tail
that is highly conserved from plants to human, suggesting a crucial
role throughout evolution. In 1998, Dr. Bill Bonner’s group at NIH
ﬁrst reported the phosphorylation of the omega-4 serine (Ser
139) in this SQ motif immediately after the introduction of DNA
damage in human cells [5]. The phosphorylated form of H2AX
was named c-H2AX because it was ﬁrst observed in cells exposed
to c-rays. Upon DSB induction, H2AX molecules are rapidly phos-
phorylated by PI3-kinases, such as ATM, ATR and DNA-PK, depend-
ing on the source of DNA damage and timing [4,6]. c-H2AX
induction is one of the earliest events detected in cells following
exposure to DNA damaging agents; it appears within minutes
and reaches maximum levels after 30 min [7]. By using speciﬁc
antibodies against c-H2AX several important ﬁndings have been
demonstrated. First, H2AX phosphorylation occurred in the chro-
matin surrounding a DSB site. Second, hundreds to thousands of
c-H2AX molecules surround one DSB to form a focus which may
function both to open the chromatin structure and to serve as a
platform for the accumulation of many factors involved in the
DNA damage response [8,9].
Since its discovery, the c-H2AX assay has been largely used for
basic research to better understand the cellular mechanisms of
different DNA damage repair pathways. In fact, many novel pro-
teins involved in DNA damage response have been identiﬁed by
their interaction and/or co-localization with c-H2AX ([8,10–14]
and Fig. 1). They sequentially assemble in a time-dependent man-
ner [8,14]. The accumulation of repair and signaling factors is a
facilitating and amplifying step of signal transduction and check-
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be mediated through interactions between SQ motif and speciﬁc
domains of repair/signaling proteins. Knock-out of H2AX causes a
pleiotropic phenotype of radiation sensitivity, growth retardation,
immunological deﬁciency and sterility of male mice. It is also asso-
ciated with chromosomal instability and defective DSB repair [15].
As an adjunct to such basic studies, especially in the last 5 years,
there has been an increasing use of c-H2AX in translational studies
to measure the biological effects of DNA damaging agents used in
both chemotherapy and radiotherapy [16], including drug discov-
ery and in vitro testing [17,18]. Indeed, this accelerating trend
has prompted this review.
Given the nexus between DNA double-strand breaks (DSBs) and
the c-H2AX response, the use of the latter to monitor biologically
important DNA damage invokes two assumptions that must be
acknowledged. The ﬁrst of these is that DSBs represent the only
form of critical DNA damage. Whilst it is clearly established that
a single unrepaired DSB can cause cell-killing, chromosome insta-
bility and gene mutation which may result in carcinogenesis
[19], clustered oxidative DNA lesions (OCDLs) are also important.
OCDLs (two or more oxidative DNA lesions generated within 10
base pairs of each other) can also result in detrimental cell conse-
quences; they are difﬁcult to repair and contribute to mutagenesis
[20]. However, DSBs can be generated by the process of repairingFig. 1. c-H2AX formation and its role in the irradiation-induced DNA repair foci. The foci
(MRE11-RAD50-NBS1) complex, recruitment of the ATM kinase and its autophosphorylat
allows the recruitment of MDC1. MDC1 binding to c-H2AX, in turn, allows the enrollmen
ATM will then permit accrued phosphorylation of H2AX and other DNA repair proteins
ubiquitin ligase which initiates histone H2 (H2AX, H2A, H2B) poly-ubiquitylation at DSB
including proteins and/or protein complexes such as the BRCA1 A complex, 53BP1, RAD
remodeling complexes and chromatid cohesins. Foci formation is thought to stimulate
chromatid cohesion and to facilitate cohesion of broken chromosome ends. P: phospha
histones are shown.OCDLs [21,22], so it seems reasonable to assume that these two
types of lesions are not mutually exclusive. The second assump-
tion, that exogenous DNA damaging agents are the only source of
DSBs, is of more concern, and is addressed in Section 7.
Inspection of Fig. 1 raises the question as to why c-H2AX has
attracted so much attention, as well as the possibility that other
repair proteins might provide a better basis for an assay of DNA
damage. Indeed many such proteins, such as 53BP1, RAD50,
MRE11, NBS1, phospho-ATM and many others can also be de-
tected as repair foci. Part of the answer to this may simply re-
side in the historical momentum; the literature is dominated
by c-H2AX. However an important feature of c-H2AX is that it
is a new species induced by DSBs formation, whereas 53BP1
for example forms foci by translocation. Also, there is consider-
able evidence of the heterogeneity of foci formation by many
other DNA damage repair proteins. Some, such as 53BP1, NBS1
and MRE11 are dissociated from DNA damage foci in the
mitotic stage, whereas c-H2AX foci are formed throughout the
cell cycle [23–25]. Finally, c-H2AX is a universal DSB marker.
As mentioned above, SQ motif is highly conserved and H2AX
phosphorylation occurs upon DNA damage induction across spe-
cies [10]. This characteristic is quite advantageous and allows
clinical researchers to use this biomarker to evaluate treatment
efﬁcacy in other species before translational applications.assembly is a hierarchical process which starts with the DSB recognition by the MRN
ion at the DSB site. The resulting ATM-mediated phosphorylation of H2AX (c-H2AX)
t of other proteins including the MRN complex and ATM. Additional recruitment of
concentrating at the DSB (RNF8, BRCA1, 53BP1, etc.). MDC1 also recruits RNF8, an
sites. These histone modiﬁcations allocate a second wave of protein accumulation,
18, PTIP, EXPAND1, etc. c-H2AX is also involved in the recruitment of chromatin
DNA repair and checkpoint activation, to allow chromatin remodeling and sister
te, Ub: ubiquitin, me: methyl, M: MRE11, N: NBS1, R: RAD50. To simplify, single
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drug and irradiation responses in cancer patients as well as to im-
prove clinical protocols. We also discuss the options available to
clinicians for biospecimen sampling and the techniques employed
for c-H2AX analysis.
2. Assays for c-H2AX detection and choice of biospecimens
The detection of c-H2AX relies on immunological techniques
using speciﬁc monoclonal and/or polyclonal antibodies against
the H2AX C-terminal phosphorylated peptide CKATQAS(PO4)QEY
[26]. Total c-H2AX levels can be measured either in cell and/or tis-
sue lysates or directly in cells and tissues [4]. In the ﬁrst approach,
the techniques establish the overall c-H2AX levels in lysates by
using immunoblotting or the enzyme-linked immunosorbent assay
(ELISA) [27,28]. While immunoblotting is a useful tool for basic re-
search, a lack of sensitivity generally makes this system unpractical
for clinical samples. However, the high sensitivity of the ELISA re-
cently allowed this technique to be developed for clinical trials
[27]. In the second approach, c-H2AX levels are measured directly
in cell nuclei by microscopy or ﬂuorescence-activated cell sorting
(FACS). Several reasons make microscopy the method of choice to
detect c-H2AX levels in patients’ samples (Tables 1 and 2). First,
large numbers of c-H2AXmolecules formed at DNA break sites cre-
ate bright foci that allow detection of individual DSBs making foci
counting the most sensitive assay to detect DNA damage. Second,
only microscopy reveals valuable information inaccessible by other
methods, such as a differential response in tumor tissues (non-
homogeneous vs. homogenous DNA damage induction) and the
extent of DNA damage (separate foci in weakly damaged cells vs.
pan-staining in suspected apoptotic cells).
The c-H2AX assay has been applied for a variety of human tis-
sues and cells. The best way to monitor the efﬁciency of cancer
therapy would be to directly assay tumor biopsies [29], although
a high variability of responses can occur due to cellular heteroge-
neity and vascularization. Another means to directly assay cancer-Table 1
Non-exhaustive list of clinical studies using the c-H2AX assay to measure the effects of chem
studies while the bottom part contains some studies obtained from the ClinicalTrials.gov
Tissues analyzed Drug(s) Condition
PBMCs Clofarabine and cyclophosphamide Refractory acute leukem
PBMCs/tumor
biopsies
SJG-136 Solid tumors
AML marrow
blasts
Combination of tipifarnib and etoposide AML
PBMCs Combination of 5-azacytidine and
entinostat
MDS, chronic myelomo
Plucked eye-
brows
Olaparib (AZD2281) Breast cancer
CTCs/PBMCs Combination of veliparib (ABT-888)
with topotecan
Solid tumors and lymph
Tissues analyzed Drug(s) Condition
ClinicalTrials.gov
PBMCs, skin,
hairs
Veliparib (ABT-888) Breast, ovarian, pancrea
BRCA2 mutations carrie
Tumor biopsies 7-t-butyldimethylsilyl-10-
hydroxycamptothecin
Solid malignancies
N/A BSI-201 (Iniparib) Advanced solid tumors
N/A Combination of BSI-201 and
temozolomide
Glioblastoma
N/A BSI-201 (Iniparib) Ovarian cancer
N/A TH-302 Glioma
N/A Combination of gemcitabine,
carboplatin and BSI-201
Triple negative breast c
N/A Combination of gemcitabine/
carboplatin plus BSI-201
Breast cancerous cells is by using circulating tumor cells (CTCs) [27]. Because
CTCs have detached from primary or metastatic tumors, they circu-
late in the bloodstream and can be isolated from patients’ blood
samples [30]. Consequently, treatment leading to DNA damage in
tumors can result in the release of CTCs bearing c-H2AX-detectable
DSBs. Wang et al. showed dynamic changes in CTC numbers in cir-
culating blood, as well as increased c-H2AX levels in cancer pa-
tients undergoing chemotherapy and demonstrated the promise
to utilize such cells to monitor the effects of DNA damaging agents
on tumors in future clinical trials [27].
However, inmost cases collecting tumor samples is a challenging
medical procedure, especially when repeated samplings are re-
quired. Therefore, clinicians often have to turn to safer, less invasive
procedures that can be used routinely in the clinic, and will help
evaluate the response to therapy as well as to ensure that reproduc-
ible results can be obtained. Cytotoxicity in normal tissues is an
important side-effect of anti-cancer therapy, which can be moni-
tored in tissues that can be obtained with minimal invasiveness.
Skin punch biopsies retain most of the skin layers including pro-
liferating keratinocytes [31]. These tissues can be used for studies
of the side-effects and efﬁciency of radiotherapy as well as the
activity of drugs interfering with DNA metabolism [32].
Peripheral blood lymphocytes are the most common and easiest
cells to obtain to analyze c-H2AX formation in vivo. Under normal
conditions (i.e., prior to DNA damage induction), lymphocytes
show low c-H2AX levels, typically less than one c-H2AX focus
per cell [33]. DSB induction leads to formation of large and bright
c-H2AX foci in response to as little as 1.2 mGy (equivalent to an
average of 0.1 foci per cell) [34].
The c-H2AX assay can also be performed in exfoliated oral epi-
thelial (buccal) cells [35]. Exfoliative oral cytology has been previ-
ously advocated as a simple and non-invasive diagnostic technique
[36,37]. Buccal cells are collected by mouthwash or scraping the
patient’s inner cheeks with a swab [35,38]. However, c-H2AX
quantiﬁcation in such samples could be problematic as the collec-
tion of cells from the oral mucosa often leads to a highly heteroge-otherapeutic drugs in cancer patients. The top of the table includes published clinical
database.
c-H2AX
detection
Phase References
ias FACS I [64]
M I [65]
FACS I [64]
nocytic leukemia, and AML I I [68]
M I [39]
omas M I [67]
c-H2AX
detection
Phase ClinicalTrials.gov
identiﬁer
tic, prostate cancers; BRCA1,
rs
N/S I NCT00892736
M/I I NCT01202370
N/S I NCT01161836
N/S I, II NCT00687765
N/S II NCT01033123
M/I II NCT01403610
ancer N/S II NCT00813956
N/S III NCT00938652
Table 2
Non-exhaustive list of clinical studies using the c-H2AX assay for various radiobiological applications: biodosimetry, radiosensitivity, prediction of the normal tissue side effects
of radiotherapy alone or in combination with chemotherapy in cancer patients.
Tissues analyzed Treatment Condition, measured effects c-H2AX
detection
References
Skin biopsy 0.05–1.1 Gy, ﬁrst week of RT Prostate cancer, normal tissue reactions M [32]
PBMCs CT of benign or malignant
neoplasms
Thorax and/or abdomen, biodosimetry M [81]
PBMCs RT or RCT Different tumors in different locations, biodosimetry M [72]
PBMCs 3D conformal- vs. step-and-shoot
IMRT
Prostate cancer, biodosimetry M [85]
PBMCs CT angiography Biodosimetry M [82–84]
PBMCs Radionuclide therapy (131I) Thyroid cancer, normal tissue toxicity M [96]
PBMCs Ex vivo irradiation Different tumors in different locations in children, radiosensitivity M [117]
PBMCs 60–66 Gy, 2 Gy/fraction, RT or RCT Head-and-neck cancer, oral mucositis, radiosensitivity M [127]
PBMCs Ex vivo irradiation Cervix and endometrial cancer, late normal tissue reactions,
radiosensitivity
M [125]
PBMCs Ex vivo irradiation Head and neck cancer, acute normal tissue reactions, radiosensitivity M [126]
PBMCs Ex vivo irradiation Different tumors in different locations, late tissue reactions,
radiosensitivity
FACS [123]
T-cell lines Ex vivo irradiation ATM and NBS syndrome, radiosensitivity M [119]
Lymphocyte cell
lines
Ex vivo irradiation Different tumors in different locations, late tissue reactions,
radiosensitivity
M [114]
Abbreviations: M, microscopy; I, immunoblotting; FACS, ﬂuorescence-activated cell sorting; CTCs, circulating tumor cells; PBMCs, peripheral blood mononuclear cells; MDS,
myelodysplastic syndrome; AML, acute myeloid leukemia; N/S, not speciﬁed; CT, computed tomography; RT, radiotherapy; RCT, radiotherapy in combination with che-
motherapy; ATM, ataxia telangiectasia; NBS, Nijmegen breakage syndrome.
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Finally, recent studies and clinical trials with cancer patients, as
well as animal studies, show the potential of using plucked hairs to
visualize c-H2AX formation in vivo following exposure to both
genotoxic drugs and radiation [39,40]. Samples can be obtained
by plucking scalp and eyebrow hairs. A major advantage of the
use of hair follicles rather than peripheral lymphocytes is that
plucked hairs contain replicating cells that are more vulnerable
to cancer drugs targeting DNA replication [41].
3. Development of high throughput systems for counting c-
H2AX foci
Although the most common approach is to manually count c-
H2AX foci either directly by eye with a microscope or in images
previously captured, it is laborious, time consuming and a subject
to a human error. Therefore, there is a clear incentive to develop
high throughput foci counting systems for research and routine
clinical assays. Validation of these automated systems unavoidably
relies on comparisons with manual counting, but once achieved,
enables extension to the analysis of foci size, and intensity. More-
over, the rapidity of automatic counting enables analysis of foci
counts and other parameters amongst a population of cells much
more feasible compared to manual counting.
To optimize the methods of c-H2AX assessment and detection,
number of studies came up with suggestions on the optimization
of sample preparation [42], imaging modalities in cell cultures
and in tissues [43–45], cytometric assessment of H2AX phosphor-
ylation [46], automated microscopy and image processing [47,48],
and led to the development of image analysis algorithms incorpo-
rated into specialized software, such as TGI [48], Image J [32,49–
51], Image Pro Plus [52], Northern Eclipse [53], QuantityOne [54],
AnalySis [55], Foci 8.0 [56], Histolab™ [57], Foci Counter [58],
and others.
A detailed comparison of the available software is beyond the
scope of this review, but some general notes of caution are appro-
priate. An automated foci counting requires thoughtful adjustment
of the microscope settings, and analysis can be performed only on
high quality images, taken with identical laser power and intensity,
exposure and resolution settings. In addition, the resulting values
are highly sensitive to the settings applied to the scored images,such as threshold, h-dom, and top hat. The values chosen for these
settings can markedly impact on the outcome values. A simple
illustration is that increase in threshold leads to lower foci counts.
As with manual counting, the foci overlap can lead to their under-
scoring. A careful visual inspection of the derived foci and compar-
ison to the original images is needed to deﬁne the optimal settings
in automated high throughput image analysis. One of the most re-
cently developed software, TGI, is an efﬁcient program [48] for fast
and reliable foci counting co-localization and intensity analysis. It
includes the optimized automated nuclei identiﬁcation for com-
plex images of tissues that contain overlapping objects. The pro-
gram enables automatic batch processing of a series of images.
Recent developments in automation have been incorporated
into high throughput analysis platforms. The RABiT (Rapid Auto-
mated Biodosimetry Tool for Radiological Triage), a fully auto-
mated robotic system for sample preparation, staining, image
acquisition and analysis, is currently under development at Colum-
bia University, New York [59–62]. Designed to be used for high
throughput biodosimetry, it explores the micronucleus assay for
delayed time points and the c-H2AX intensity (rather than foci
counts) for detection of recent events. Although developed to han-
dle very large numbers of samples for dosimetry screening in re-
sponse to radiation incidents, such systems would be adaptable
to routine clinical investigations.
4. c-H2AX is a biomarker in cancer chemotherapy
Since its discovery, c-H2AX has been extensively used in basic
research in molecular pharmacology (see [18,63] for example),
but its application as a pharmacodynamic marker in clinical stud-
ies is a relatively recent development [64]. In the last 4 years there
has been a sharp increase in its use to monitor chemotherapy-in-
duced DNA damage in cancer patients. Examples of the use of c-
H2AX in clinical studies are shown in Table 1 and can be found
in clinicaltrials.gov. Since microscopy can discriminate between
cells with low DNA damage (foci pattern) and cells potentially
going through apoptosis (c-H2AX panstaining), it is the preferred
option for c-H2AX analysis in patients’ samples ([16] and Table 1).
To date, there has been more than 35 clinical trials using c-H2AX
for evaluation of drug response in cancer patients. Of the four
phases of clinical trials involved in the cancer drug-development
process, there have been reports of the use of c-H2AX as a bio-
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assess drug safety and pharmacokinetics, comprises more than half
of total reported protocols using c-H2AX. The c-H2AX assay has
been used to scrutinize the effects of various drugs that differ in
the type of DNA damage they generate (topoisomerase I inhibitors,
PARP inhibitors, DNA-alkylators, etc.). For example, in a phase I
dose-escalation study aimed to establish the maximum tolerated
dose of the sequence-selective minor groove DNA binding agent
SJG-136 in patients with advanced solid tumors, evidence of
drug–DNA interaction was shown through the formation of c-
H2AX foci in lymphocytes and tumor cells [65]. The practical use
of the marker for pharmacodynamics was furthermore demon-
strated in a phase I clinical trial after examination of c-H2AX levels
in another normal tissue – plucked eyebrow hair follicles from pa-
tients treated with a Poly(ADP-ribose) polymerases (PARP) inhibi-
tor. This study showed a clear relationship between c-H2AX levels
and PARP inhibition [39]. Nevertheless, the majority of clinical pro-
tocols currently use c-H2AX to investigate the efﬁcacy of drug
combinations. Such trials often combine a PARP inhibitor (i.e., ola-
parib and veliparib) with a DNA damaging agent (i.e., mitomycin C,
carboplatin, cyclophosphamid, etc.). PARP inhibitors are com-
pounds that speciﬁcally target the PARP-1, PARP-2 and tankyrase
1 (although PARP-1 is the most abundant PARP) (reviewed in
[16]). PARP enzymes are strongly activated by both DNA single-
strand breaks (SSBs) and DSBs, but because of their major contribu-
tion in DNA SSB repair, their inhibition has been proposed to lead
to increased DSB formation [16]. For this reason, the use of PARP
inhibitors (alone or combined with a DNA damaging agent leading
to SSB) is a promising tool for killing tumors carrying defects in
genes involved in DSB repair such as the BRCA1 and BRCA2 genes
[66]. An illustration of the beneﬁts of including the c-H2AX assay
in such protocols comes from a phase I study using ABT-888 (veli-
parib) in combination with topotecan hydrochloride, a topoisomer-
ase I inhibitor in adults with lymphoma and refractory solid
tumors [67]. Analysis of CTCs, tumors and mononucleated blood
cells revealed increased c-H2AX signals in patients receiving
ABT-888 with topotecan. Thus, the studies proved that PARP inhi-
bition can modulate the capacity to repair topoisomerase I-medi-
ated DNA damage in vivo in cancer patients.
In a study of another drug combination, DNA methyltransferase
inhibitorsaloneor incombinationwithhistonedeacetylase inhibitors
which demonstrated clinical efﬁcacy in patients with myelodysplas-
tic syndrome(MDS)oracutemyeloid leukemia (AML), also resulted in
increased c-H2AX levels in peripheral blood lymphocytes [68].
Overall, while c-H2AX is a newcomer in the array of clinical bio-
markers, its use has become an important inclusion for most DNA
damage repair studies. It is reasonable to think that because of its
sensitivity, efﬁcacy and convenience, more cancer clinical trials
will take advantage of this marker in the future.5. Biodosimetry
Although potentially a very generic term, ‘‘biodosimetry’’ is now
commonly used in the context of retrospective estimation radia-
tion dose from the extent of biological damage resulting from acci-
dental radiation exposure; especially in scenarios when no
physical dose estimate is available. Over the past decades, the most
commonly used method in biological dosimetry was cytogenetic
analysis, in which the stable (translocations) and unstable (dicen-
tric chromosomes, micronuclei) chromosomal aberrations are
counted in peripheral blood lymphocytes, along with a few other
methods such as the glycophorin A mutation assay, electron para-
magnetic resonance in tooth enamel, and the comet assay [69,70].
However, cytogenetic analysis is time-consuming; it implies
growth stimulation for 48–72 h since chromosomal damage canonly be measured in metaphases [71]. Thus, such an analysis is
not suitable for the rapid identiﬁcation of the most severely ex-
posed individuals, which is required in the event of a large-scale
radiation emergency, when reliable detection is needed for popula-
tion triage during the ﬁrst few hours after accidental radiation
exposure.
Now the c-H2AX assay has emerged as the preferred method.
First, it has the advantage of the short time frame of the assay,
and in the addition the high sensitivity; it can detect DNA damage
induced by radiation doses as low as 1.2 mGy [34]. Measurement
of DNA damage-induced c-H2AX foci in lymphocytes avoids cell
cycle effects since unstimulated lymphocytes are non-cycling cells.
Many radiation accidents involve inhomogeneous exposures or
partial body irradiation, and the c-H2AX assay can be used to esti-
mate the dose delivered to the whole body even if only a part of the
body was irradiated, due to the redistribution of lymphocytes in
blood ﬂow [72,73].
Apart from retrospective evaluation of the absorbed dose in
cases of accidental exposure to IR, and other scenarios such as in
air and or space traveler [74], c-H2AX-based biodosimetry has
widespread clinical applications, summarized in Table 2. These
applications involve patients undergoing radiological diagnostic
or therapeutic treatments (CT scan, angioplasty, radiotherapy,
etc.). There is similar potential in counterpart preclinical studies,
as exempliﬁed by the use of measurements of c-H2AX levels in
the development of a new micro-computed tomography-based
conformal radiotherapy in a mouse model [75].
Interestingly, the numerous reports, include clinical studies,
have established and validated the linear radiation dose response
of the c-H2AX assay [34,40,53,72,76–78], a necessary feature of a
reliable biological dosimetry. For example, the linear correlation
was shown between the numbers of c-H2AX foci per lymphocyte
obtained from peripheral blood samples and the integrated total
body radiation dose in cancer patients treated with 3D conformal
radiotherapy for a variety of tumor types [72], therefore making
it possible to estimate the applied integral body dose, of course
with consideration of the irradiation site and time dependence.
Ex vivo irradiation of freshly obtained lymphocytes resulted in
induction of 10–15 foci per Gy [34,57,76], and no inter-individual
heterogeneity was detected. However, high inter-individual vari-
ability was observed by Andrievski and Wilkins [77] which might
be attributed to the applied dose of 10 Gy, as well as the use of
FACS for quantiﬁcation of H2AX phosphorylation. A number of
studies have demonstrated that the c-H2AX levels after in vivo
exposure depend on the dose, exposed area of the body, and the
duration/fractionation of the exposure. The c-H2AX assay allowed
demonstration of the localized irradiation of the mouse brain with
CT-guided precision device [79]. The detailed study to characterize
the in vivo formation and repair of DNA DSBs after CT examinations
was performed by Lobrich et al. [80]. Interestingly, the study re-
vealed that the repair kinetics of induced DNA damage appeared
to be more efﬁcient in vivo rather than in vitro. Phantom dosime-
try-calculated total blood doses (13.85 mGy with whole-body CT
and 5.16 mGy with chest CT) were conﬁrmed by c-H2AX-based
dosimetrical estimations (16.4 mGy and 6.3 mGy) [81]. The studies
of Kuefner et al. [82–84] adapted the c-H2AX assay to assessment
of DSB induction and repair in peripheral blood lymphocytes in pa-
tients undergoing angiographic procedures. A linear correlation
was found between c-H2AX kinetics and the radiation doses
delivered during procedures; the assay has been considered to
measure patients’ individual repair capacity. Zwicker et al. [85]
investigated the differences in dose delivery between SSIMRT
and 3D treatment modalities of prostate cancer using c-H2AX for
biodosimetrical estimations. The results revealed a similarity be-
tween the c-H2AX based measurements of the exposure of lym-
phocytes and physical dosimetry. Lower dose exposure of
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to the 3D conformal treatment mode, and high dose exposure was
the same in both cases. c-H2AX measurements in skin biopsies ta-
ken from prostate cancer patients undergoing radiotherapy re-
vealed a linear dose response and individual sensitivity to
radiotherapy [32].6. Monitoring effects of radionuclide therapy
The well-established phenomenon that decay of the Auger emit-
ter 125I, when incorporated into DNA, generates highly focused DNA
damage [86]which corresponds to oneDNADSBper radioactive dis-
integration, and this has been used to correlate c-H2AX foci with
DSBs in cell cultures treated with 125IdU. In S-phase synchronized
cells, the data showed a direct correlation between the number of
125I decays/DSBs and the numbers of foci per cell [87]. Studies with
DNA binding ligands labeled with 125I demonstrated that DNA
breaks can be induced by Auger decay non-covalently associated
with DNA with subsequent cytotoxicity, initially with intercalating
ligands [88,89], and subsequently with minor groove-binders
[90,91]. This prompted the strategy to deliver Auger-induced dam-
age to genomic targets by triplex-forming oligonucleotides (TFOs)
that bind speciﬁcally to their target sequences by forming hydrogen
bonds within the major groove of the target duplex. This approach
has been named antigene radiotherapy [92]. The c-H2AX assay has
been used to screen the wide variety of possible TFO modiﬁcations
and proved to be useful for evaluation of cellular DNA accessibility
of 125I-labeled DNA targeting agents [93,94].
The c-H2AX assay has also been used to monitor formation and
persistence of DNA damage and cytotoxicity in human cancer cells
produced by another Auger emitter, 111In, that has been delivered
to cell nuclei by pharmaceuticals that target human epidermal
growth factor receptor (EGFR)-positive cancers and HER2/neu-
ampliﬁed breast cancers [49,50]. In another study, c-H2AX levels
increased in cultured tumor cells conﬁrming the genotoxic effect
of radioimmunotherapy with alpha-particle emitting 213Bi. The
anti-tumor efﬁcacy of this therapy was conﬁrmed in a mouse mod-
el [95]. However, in a real clinical situation, during radionuclide
therapy, directly targeted tumors are often not accessible; rather,
normal tissue response to a circulating radionuclide (direct or by-
stander) can be monitored.
Radionuclide-induced DNA damage induction and repair kinet-
ics in vivo can be very complex due to several factors. First, many of
radionuclides used for therapy emit photons, heavy ion particles,
and electrons; and collectively represent a wide range of intensity
and distribution (within cells and at an organ level) of radiochem-
ical damage. Second, the pharmacokinetics of radionuclide expo-
sure is determined by the biochemical carrier and hence
intracellular location. Third, the time course of radiation delivery
is determined by the physical rate of exponential decay of a radio-
isotope as well as the pharmacokinetics of the carrier. Finally, there
can be variations in radiosensitivity between patients, and also for
particular patients, there can be different responses to consecutive
rounds of treatment. In fact, the only in vivo study reported that the
formation, persistence and disappearance of c-H2AX and 53BP1
foci in mononuclear blood cells of patients with differentiated thy-
roid cancer after 131I therapy varied dramatically between
individuals [96]. Monitoring of this normal tissue response in par-
allel with the clinical tumor outcome, could also form a basis for
routine monitoring of individual radiosensitivity to the therapy.7. Individual radiosensitivity
Another important potential application of c-H2AX assay is the
assessment of radiosensitivity of prospective patients. Radiationtherapy is the major cancer treatment modality either alone or in
combinationwith chemotherapyor surgery.However, in somecases
it can induce severe sideeffectsdue tonormal tissue toxicity. Inmost
schedules of radical radiotherapy aiming for local tumor control, the
dose prescribed results in5% of patients experiencing severe side-
effects. If the radiosensitive subpopulation could be identiﬁed in ad-
vance, customized radiotherapy treatments could avoid the severe
side effects of the subpopulation, and enable safe escalation of dose
in themajority of patients with normal radiosensitivity. The clinical
challenge is not new, andmany studies have addressed thenecessity
of developing the rapid, reliable and functional assays to predict the
individual radiosensitivity [97–99].
The radiosensitive patients show pronounced clinical radiation
reactions, such as acute effects (erythema, edema, mucositis, dry
or moist desquamation) and late effects (telangiectasia, ﬁbrosis,
cancer induction, neurological effects and others). Up to 70% of
cases of increased radiosensitivity remain unexplained, and indi-
vidual differences in intrinsic cellular radiosensitivity, resulting
from genetic variations and epigenetic factors might contribute
to their occurrence [100].
Radiosensitivity is often observed in patients with genetic dis-
orders associated with a defect in the DNA damage response and
cell death pathways (reviewed in [101–103]). Among these are
such well characterized syndromes as AT, AT-like disorder, Nijme-
gen breakage syndrome (NBS), Fanconi anemia (FA), Ligase IV syn-
drome, Seckel syndrome, Li-Fraumeni syndrome and familial
retinoblastoma. Pollard et al. [104] reviewed 32 cases of over-
reacting individuals, half of them were FA patients, who developed
adverse reactions in response to radiotherapy. Most of them died
within several months after radiation exposure took place. In addi-
tion to higher incidence of cancer and increased susceptibility to
radiation, they are often associated with defects in immune and
neurological systems. So far about 150 DNA repair genes have been
identiﬁed, and the real number is probably higher, since the func-
tion of a signiﬁcant part of known and putative genes in human
genome has not been described yet [105,106].
Radiosensitivity is associated with deﬁciency in important cell
functions, such as cell survival, DNA repair capacity, formation of
chromosomal aberrations, and induction of cell death [107]. There-
fore, in vitro measurements of cell functions have been used as
endpoints to evaluate individual radiosensitivity. Several assays
were tested for their potential to predict radiosensitivity by mea-
suring DNA repair capacity, induction of cell death and cytogenetic
effects, and ability of cell to survive and retain their proliferative
capacity after irradiation [107]. Chromosomal aberrations (dicen-
trics and translocations) and clonogenic survival were shown to
be able to predict intrinsic radiosensitivity [108–110]. However,
these assays require cell activation or transformation, and the time
required to produce the data varied from days in case of cytoge-
netic tests in lymphocytes (dysenteric chromosomes, micronuclei,
translocations, DNA fragments) to months for clonogenic survival.
It has been reported that transformation itself may disrupt the
radiosensitivity of normal cells [111,112]. Geara et al. [109,113] re-
ported lack of correlation between radiosensitivity of transformed
lymphocytes and primary ﬁbroblasts cultured from skin biopsy
samples. Also, a recent study by Vasireddy et al. [114] reports a
lack of correlation between radiosensitivity of transformed lym-
phocytes and clinical radiosensitivity.
The c-H2AX assay is a quick read-out of DNA damage, can be
performed on primary untransformed cells and thus presents a
new opportunity. Whether it can be a surrogate for cytogenetic
and clonogenic assays or should be considered independently is
under investigation. Scoring dicentrics and quantiﬁcation of c-
H2AX foci have been performed in lymphocytes of blood samples
exposed to a CT scanner [115]. Although they both are appropriate
methods to detect irradiation-induced damage, they quantify dif-
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H2AX foci resolve within several hours, resulting chromosomal
changes can be present for long time forming a base for normal tis-
sue toxicity, and can be quantiﬁed by scoring of chromosome aber-
rations. However, the number of residual c-H2AX foci at 12 or 24 h
post-irradiation was found to correlate with clonogenic survival
and to predict differences in the radiation dose response relation-
ship in vitro [56,116].
Addressing the question whether the c-H2AX post-exposure
kinetics correlates with clinically relevant endpoints evoked sev-
eral recent studies. The c-H2AX screen of lymphocytes from chil-
dren with solid cancers identiﬁed three patients with impaired
DSB repair capacities, and two of these repair deﬁcient children
developed acute normal tissue toxicities in response to DNA dam-
aging cancer therapy [117]. Lobrich et al. [80] examined c-H2AX
induction in CT patients, and identiﬁed impaired kinetics of c-
H2AX foci in one radiosensitive patient. Analysis of c-H2AX foci
in cell lines derived from patients with severe or mild mutations
in a core non-homologous end joining (NHEJ) factor, or mutations
in ATM signaling pathway or Artemis allowed the identiﬁcation of
distinct typical DSB repair proﬁles associated with defects in early,
late, or both early and late rejoining [118]. In mouse strains with
various DSB repair deﬁciencies, even slight genetic impairments
were reﬂected by the c-H2AX assay in lymphocytes and tissues
after total body irradiation [45].
The assay has already successfully identiﬁed AT, NBS, xero-
derma pigmentosum, FA, retinoblastoma, Ligase IV syndrome pa-
tients and others [114,119–122]. Recently, the new translational
opportunities of the c-H2AX assay attracted attention of several
international groups, but the reported results are somewhat con-
tradictory. One study reports successful identiﬁcation of radiosen-
sitive patients based on their lower response to 1 Gy irradiation
in primary lymphocytes and maintaining this unrepaired damage
for longer time (12 out of 12 radiosensitive patients exhibited re-
pair delay) [123], while another study suggests that low doses are
the most effective for the difference detection [124]. However,
other reports failed to prove the usefulness of this assay. Wer-
brouck et al. [125] found no difference in foci kinetics in irradi-
ated ex vivo T-lymphocytes between the non to mild and
moderate to severe late normal tissue reactions in gynaecological
cancer patients, nor was there any correlation between the assay
and acute normal tissue reactions during IMRT treatment in head
and neck cancer patients [126]. The study of Fleckenstein et al.
[127] did not reveal the difference between grade 3 and grade
2 mucositis with c-H2AX foci counts estimated 24 h after radia-
tion exposure, as well as DSB repair half times, although the
authors established that the patients with an increased unre-
paired DSBs after 24 h had an increased incidence of severe oral
mucositis.
The apparent controversy as to the reliability of the c-H2AX as-
say in assessing individual radiosensitivity prompts consideration
of the importance of the cell cycle in the assay endpoint. Progres-
sion of damaged cells through the cell cycle can lead to further
breakage in S-phase [118,128] and thus S-phase cells should be
avoided for analysis. The recommended sample tissue, peripheral
blood lymphocytes, are quiescent unless activated, and therefore,
avoids interference by replication-associated DNA damage. Simi-
larly, culture of ﬁbroblasts taken as biopsy induces their accumula-
tion in G0/G1 phases of the cell cycle by contact inhibition,
therefore solving a problem of the contribution of S phase cells.
However, the fact that homologous recombination (HR) only oc-
curs in proliferating cells, imposes a dilemma for detection of
radiosensitivity due to effects in HR. A combination of assays
involving both non-proliferating and proliferating tissues (e.g.
non-activated and activated lymphocytes) might be necessary to
address this issue. Finally, it should be acknowledged that the rel-evance of lymphocyte-based assay to the complex process involved
in late radiation toxicity has been questioned [129].
Therefore, whilst the overall simplicity and high sensitivity is
attractive, the speciﬁcity of the method as a predictive assay for
identiﬁcation of radiosensitive patients is still under investigation.
At this stage, further validation of the assay is required. However,
even the correlation between the assay and clinical radiosensitivity
is incomplete, the ability of the assay to detect that subset of radio-
sensitive patients with defective DNA DSB repair pathways would
be valuable per se.8. c-H2AX -based imaging
Since anti-tumor treatments are aimed to kill tumors with min-
imal side effects to normal cells, direct imaging of DNA damage
in vivo has a great potential for monitoring therapeutic efﬁcacy
and patients’ responses to chemo- and radiotherapy. Such in vivo
imaging would also have a great diagnostic as well as prognostic
advantage if increased DNA damage levels in various organs asso-
ciated with genome instability, chronic inﬂammations and early
carcinogenesis [130–134] are identiﬁed.
Until recently, quantiﬁcation of DNA damage in vivo was not
possible; rather, an approach to measure apoptosis in vivo has been
developed. Annexin V, a protein with high activity to apoptotic
cells, has been labeled with different tags, ﬂuorochromes and
radionuclides [135–138]. Development of small amphipathic mol-
ecules accumulating in apoptotic cells is another approach [139].
Edgington et al. [138] describe the use of ﬂuorescently-labeled
probes conjugated with cell-permeable peptide sequence, that
covalently label activated caspases in mice with induced apoptosis.
However, apoptosis in tumors is not the only outcome of anti-can-
cer therapy; other processes such as necrosis, mitotic catastrophe,
autophagy and senescence also play a role.
Since DNA DSBs are involved in multiple biological processes
including apoptosis, imaging of DSBs in vivo would be much more
informative. However, DSB levels are generally low (difﬁcult target
for imaging), and they are not easy to access because of their nucle-
ar location. Two very recent studies explore the opportunity to di-
rectly visualize DSBs in vivo. Detection of the c-H2AX signal
ampliﬁed at the sites of DSBs in a megabase region [4] is the strat-
egy to overcome their low numbers. Cornelissen et al. [140] devel-
oped a strategy to detect c-H2AX in vivo by a cell-penetrating Tat
peptide containing a nuclear localization signal (NLS) sequence.
When this peptide is attached to a ﬂuorophore- or 111In-labeled
anti-c-H2AX antibody, it labels phosphorylated H2AX in live cells
and mice following DNA damage.
A quite different strategy described in [141] is based on the fact
that c-H2AX is physically associated with MDC1 DSB repair pro-
tein. Thus, N- and C-terminal fragments of ﬁreﬂy luciferase genes
were fused with H2AX and MDC1 genes, respectively. In live mam-
malian cells, upon a DSB formation, H2AX is phosphoryated and
associates with the MDC1 bringing together N- and C-luciferase
fragments and reconstituting luciferase activity. Although this
innovative approach is peripheral to translational oncology, it has
revealed new radiobiological information. For example, the
authors detected a second wave of DSB induction in irradiated
transplanted tumors days after radiation exposure in vivo, in addi-
tion to the initial rapid induction of DSBs.9. Conclusions
The widespread versatility and potential of the c-H2AX assay
for translational studies stem mainly from two features of the as-
say. Firstly, its sensitivity enables quantiﬁcation of the biological
effects of low doses particularly in the context of radiation biodos-
130 A. Ivashkevich et al. / Cancer Letters 327 (2012) 123–133imetry (as well as the effects of low concentrations of genotoxic
drugs and higher doses of irradiation in cancer chemo- and radio-
therapy); also the assay only requires a small sample of biological
material. Secondly the very short response time for the develop-
ment of the endpoint following induction of a DNA DSB enables
many new opportunities. Amongst these is the response of
untransformed lymphocytes to ex vivo irradiation as a means of
assessing radiosensitivity. Also the assay is amenable to automa-
tion. All these features will ensure a continuing escalation of the
application of the c-H2AX assay, particularly in translational
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